Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-12-12
2006-12-12
Epps-Ford, Janet L. (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024100, C536S024300, C536S024310, C536S024500
Reexamination Certificate
active
07148204
ABSTRACT:
Compositions and methods are provided for modulating the expression of bcl-x. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding bcl-x are preferred. Methods of using these compounds for modulation of bcl-x expression and for treatment of diseases associated with expression of bcl-x are also provided. Methods of sensitizing cells to apoptotic stimuli are also provided.
REFERENCES:
patent: 5552390 (1996-09-01), Scholar et al.
patent: 5583034 (1996-12-01), Green et al.
patent: 5627274 (1997-05-01), Kole et al.
patent: 5646008 (1997-07-01), Thompson et al.
patent: 5776905 (1998-07-01), Gibbons et al.
patent: 5834309 (1998-11-01), Thompson et al.
patent: 6110667 (2000-08-01), Lopez-Nieto et al.
patent: 6114517 (2000-09-01), Monia et al.
patent: 6172216 (2001-01-01), Bennett et al.
patent: 6214986 (2001-04-01), Bennett et al.
patent: 6248715 (2001-06-01), Rosenberg et al.
patent: WO 94/26887 (1994-11-01), None
patent: WO 95/00642 (1995-01-01), None
patent: WO 98/05777 (1998-02-01), None
Agrawal et al. (Feb. 2000) Molecular Medicine Today, vol. 6, pp. 72-81.
Branch A good antisense molecule is hard to find. TIBS, Feb. 1998, vol. 23, pp. 45-50.
Jen et al. Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Stategies. (2000) Stem Cells, vol. 18, pp. 307-319.
Crooke, S. T. Antisense Research and Application, Chapter 1, Basic Principles of Antisense Therapeutics, (1998) pp. 1-50. Springer-Verlag Press, Berlin, Heidelberg, New York.
Ma et al. 2000, Biotechnology Annual Review, vol. 5, Elsevier Science B.V.
Chu, et al., “Alternatively Processed Human E-Selectin Transcripts Linked to Chronic Expression of E-Selectin In Vivo”,J. Immunol., 1994, 153, 4179-4189.
Hodges, D., “Inhibition of Splicing of Wild-Type and Mutated Luciferase-Adenovirus Pre-mRNAs by Antisense Oligonucleotides”,Mol.Pharmacol., 1995, 48, 905-918.
Dominski, et al., “Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides”,Proc.Natl.Acad.Sci.USA, 1993, 90, 8673-8677.
Dunckley, et al., “Modification of Splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides”,Human Mol.Genetics, 1998, 5, 1083-90.
Dunckley, et al., “Modulation of Splicing in the DMD Gene by Antisense Oligoribonucleotides”,Nucleosides&Nucleotides, 1997, 16, 1665-1668.
Klasens et al., “Inhibition of polyadenylation by stable RNA secondary structure”,Nuc.Acids Res., 1998 26, 1870-1876.
Kole R., “Modification of pre-mRNA splicing by antisense oligonucleotides”,Acta Biochimica Polonica, 1997, 44, 231-238.
Moulds, C., et al., “Site and Mechanism of Antisense Inhibition by C-5 Propyne Oligonucleotides”,Biochem.1995 34, 5044-53.
Sierakowska, et al., “Repair of thalassemic human β-globin in mRNA in mammalian cells by antisense oligonucleotides”,Proc.Natl.Acad.Sci.USA, 1996; 93, 12840-44.
Sierakowska, H., “Restoration of β-Globin Gene Expression in Mammalian Cells by Antisense Oligonucleotides that Modify the Aberrant Splicing Patterns of Thalassemic Pre-mRNAs”,Nucleosides&Nucleotides, 1997, 16, 1173-1182.
Takeshima, et al., “Modulation of in Vitro Splicing of the Upstream Intron by Modifying an intra-Exon Sequence Which Is Deleted from the Dystrophin Gene in Dystrophin Kobe”,J. Clin.Invest.1995 95, 515-520.
Tuypens, et al., “Organization and chromosomal localization of the human interleukin 5 receptor α-chain gene”,Eur.Cytokine Netw., 1992 3, 451-459.
Wang, et al., “Antisense Oligodeoxynucleotdes Selectively Suppress Expression of the Mutant α2(l) Collagen Allele in Type IV Osteogenesis Imperfecta Fibroblasts”,J. Clin Invest., 1996, 97, 448-454.
Amarante-Mendes et al., “Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis:protection is correlated with up regulation of Bcl-xL”, 1998Oncogene16:1383-1390.
Boise et al., “bcl-x, a bcl-2-Related Gene that Functions as a Dominant Regulator of Apoptotic Cell Death” 1993Cell74:597-609.
Fujio et al., “Signals through gp130 Upregulate bcl-x Gene Expression via STAT1-binding cis-Element in Cardiac Myocytes”, 1997J. Clin. Invest.99:2898-2905.
Pollman et al., “Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease”, 1998Nature Med.4:222-227.
Wang et al., “Induction of bcl-x by CD40 Engagement Rescues slg-Induced Apoptosis in Murine B CeHs1”, 1995J. Immunol.155:3722-3725.
Bennett C. Frank
Dean Nicholas M.
Monia Brett P.
Nickoloff Brian J.
Zhang Vivian Q.
Epps-Ford Janet L.
Isis Pharmaceuticala, Inc.
Isis Pharmaceuticals Inc. Patent Department
O'Connor Cozen
LandOfFree
Antisense modulation of bcl-x expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense modulation of bcl-x expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense modulation of bcl-x expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3685615